California Location: Practice of Dr. Labib Hashimi adds another TOI
CERRITOS, Calif., 19 December 2022 (GLOBE NETWORKIRE) — Dr. Labib Hashimiri, Chino, CA, has been acquired by The Oncology Institute, Inc. NASDAQ: TOI). This is one of the largest US-based value-based community oncology organizations. The acquisition enhances TOI’s geographic coverage in California, with the Chino practice marking TOI’s 42nd Clinic in the Golden State
“We are excited to expand to Chino and Chino Hills, increasing access and convenience for our patients in these areas,” shared Brad Hively, CEO at TOI. “By welcoming Dr. Hashimi and his team, we are connecting our footprint in Los Angeles, Riverside, and San Bernardino Counties, allowing us to better serve patients in this community.”
This expansion comes in response to the continued strong demand for TOI’s differentiated care model which focuses on quality clinical outcomes, access for underserved populations, and value for the healthcare ecosystem.
Dr. Hashimi, former principal of Intercommunity Oncology of Chino Hills, now the TOI Chino/Chino Hills Clinic, shared, “Joining TOI is a natural fit for me and my practice. I have always kept my focus on outcomes and quality for my patients and know this partnership will benefit my patients and the Chino community.”
The Chino/Chino Hills Clinic was formerly Intercommunity Oncology of Chino Hills. It is located at 13768 Roswell Avenue, Suite 105 in Chino, Calif. 91710. (Ph. 909-591-0814). Patients will continue to be served without interruptions or a change of times.
TOI was established in 2007. It provides high-quality, value-based oncology care in the community. TOI provides cutting-edge, evidence-based, cancer care to approximately 1.7 million patients. This includes clinical trials and transfusions. TOI’s 90+ clinicians and 700+ colleagues in more than 50 clinic locations are changing the face of oncology. Visit www.toi.org for more information. www.theoncologyinstitute.com.
This press release contains statements that are not historical but are forward-looking statements to comply with the Safe Harbor provisions in the United States Private Securities Litigation Reform Act. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based both on current expectations and assumptions of The Oncology Institute. They are not predictions of actual performance. These forward-looking statements should not be regarded as a guarantee, assurance, prediction, or definitive statement of facts or probabilities. Actual events and circumstances can be difficult to predict or impossible to predict. They will vary from assumptions. The Oncology Institute is not able to predict many of the actual events and circumstances. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the company; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on the company’s business; those factors discussed in the documents of TOI filed, or to be filed, with the SEC. Actual results may differ from those implied in these forward-looking statements if the risks increase or assumptions are incorrect. The Oncology Institute does not currently know about additional risks or believe that they are immaterial. These factors could cause actual results to differ materially from the forward-looking statements. In addition, forward-looking statements reflect The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. The Oncology Institute anticipates that subsequent events and developments will cause The Oncology Institute’s assessments to change. These forward-looking statements are not subject to revision by The Oncology Institute. These forward-looking statements should not be relied upon as representing The Oncology Institute’s assessments as of any date subsequent to the date of this press release. These forward-looking statements should not be relied upon in any way.
The Oncology Institute
(562) 735-33226, x 88806